



Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults

April 2022

Table 2: Optional Lead-in, Initiation, and Maintenance for MONTHLY CAB/RPV LA Dosing [a]		
Timing	Dosing and Administration	Comments
Optional oral lead-in: Month 0	CAB 30 mg/RPV 25 mg once daily by mouth with a meal x 4 weeks	Oral medication lead-in
Month 1	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Initiation dose: Administer on last day of oral lead-in or prior suppressive ART regimen
Month 2 and every month thereafter	CAB 400 mg (2 mL)/RPV 600 mg (2 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see <i>Managing Missed or Delayed Injections</i>)
Abbreviations: ART, antiretroviral therapy; CAB, cabotegravir (brand name Vocabria); CAB/RPV LA, injectable long-acting cabotegravir/rilpivirine (brand name Cabenuva); IM, intramuscular; RPV, rilpivirine (brand name Edurant). Note: a. [FDA 2021]		

Reference

FDA. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2021 Jan.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf [accessed 2021 Mar 08]